Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00867698 · ClinicalTrials.gov registry record · Phase 2
AST-120 Used to Treat Mild Hepatic Encephalopathy
A Phase 2 study of Mild Hepatic Encephalopathy, sponsored by Ocera Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 148
- Enrollment target
- 20
- Study locations
NCT00867698 is a Phase 2 study of Mild Hepatic Encephalopathy that has completed, run by Ocera Therapeutics. The registered enrollment target is 148 participants. The trial reports 20 study locations across 11 states.
The verdict
NCT00867698, a Phase 2 study of Mild Hepatic Encephalopathy, has completed, sponsored by Ocera Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 148 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether AST-120 is safe and effective in the treatment of mild hepatic encephalopathy.
Conditions Studied
Interventions
- DRUG AST-120
Study Locations (20)
California
- UCSF - Fresno Community Regional Medical Center - Fresno
- UCSD Medical Center - La Jolla
- Scripps Clinic - San Diego
- UCSD Medical Center - San Diego
- California Pacific Medical Center - San Francisco
Florida
- University of Florida College of Medicine - Gainesville
- Mayo Clinic Jacksonville - Jacksonville
- University of Miami, Division of Hepatology / Center for Liver Disease - Miami
Illinois
- Northwestern University, Feinberg School of Medicine - Chicago
- Rush University Medical Center - Chicago
Louisiana
- Delta Research Partners, LLC - Monroe
- Tulane University Health Sciences Center - New Orleans
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconnes Medical Center, Harvard Medical School - Boston
Alabama
- University of Alabama at Birmingham - Birmingham
Arizona
- Mayo Clinic Arizona - Phoenix
Connecticut
- Yale University School of Medicine - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2009-03 |
| Est. Completion | 2010-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00867698
The ClinicalTrials.gov registry entry for NCT00867698 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 148 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ocera Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Mild Hepatic Encephalopathy appearing as the primary indexed condition, and to 1 intervention - of which AST-120 is the first listed.
NCT00867698 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT00867698 about?
NCT00867698 is a clinical study titled "AST-120 Used to Treat Mild Hepatic Encephalopathy". The purpose of this study is to determine whether AST-120 is safe and effective in the treatment of mild hepatic encephalopathy.
What is the current status of trial NCT00867698?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 148 participants. The study started on 2009-03. Estimated completion is 2010-06.
What conditions does trial NCT00867698 study?
This clinical trial studies the following conditions: Mild Hepatic Encephalopathy.
What interventions are being tested in trial NCT00867698?
The interventions under investigation include: AST-120 (DRUG).
Who is sponsoring clinical trial NCT00867698?
This trial is sponsored by Ocera Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00867698 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.